Form 4: Cytokinetics CEO Robert Blum Executes Stock Option and Sells Shares

Cytokinetics' CEO Robert Blum exercised stock options and sold 5,000 shares of common stock on November 1, 2024, according to a recent SEC filing.

Summary

• On November 1, 2024, Robert I. Blum, the President and CEO of Cytokinetics Inc., executed a non-qualified stock option to acquire 5,000 shares of common stock at a price of $6.67 per share.
• Simultaneously, Blum sold 5,000 shares of Cytokinetics common stock at a price of $51.63 per share.
• Following these transactions, Blum directly owns 397,456 shares of Cytokinetics common stock.
• He also indirectly owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.
• Blum also directly owns 64,727 non-qualified stock options.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell a portion of the acquired shares for personal financial management.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it's a routine insider transaction.

Key Dates